DDInter1297 DDInter1819
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Niraparib may lead to a major life threatening interaction when taken with Natalizumab
Niraparib may lead to a major life threatening interaction when taken with Baricitinib